ImmuPharma (LON:IMM) Trading 14.7% Higher - Time to Buy?

Key Points

• ImmuPharma's shares surged 14.7% on Thursday, reaching a trading high of GBX 13.95 ($0.19) before closing at GBX 12.50 ($0.17), even as trading volume decreased significantly.
• The company reported a negative earnings per share of GBX (0.38) for the last quarter, with analysts forecasting a projected EPS of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with their lead program, Lupuzor™, targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded up 14.7% on Thursday . The company traded as high as GBX 13.95 ($0.19) and last traded at GBX 12.50 ($0.17). 2,095,833 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 8,385,633 shares. The stock had previously closed at GBX 10.90 ($0.15).

ImmuPharma Price Performance

The stock's 50 day simple moving average is GBX 8.52 and its two-hundred day simple moving average is GBX 4.55. The stock has a market cap of £61.08 million, a P/E ratio of -13.65 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.